Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis

被引：57

作者：

Muro, Yoshinao ^{[1
]}

Sugiura, Kazumitsu ^{[1
]}

Akiyama, Masashi ^{[1
]}

机构：

[1] Nagoya Univ, Dept Dermatol, Grad Sch Med, Div Connect Tissue Dis & Autoimmun,Showa Ku, Nagoya, Aichi 4668550, Japan

来源：

CLINICAL RHEUMATOLOGY | 2013年 / 32卷 / 03期

关键词：

Anti-MDA5; antibody; Dermatomyositis; Ferritin; IL-18; Interstitial lung disease; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; GENE; 5; AUTOANTIBODIES; COMPLICATION; AUTOANTIGEN;

D O I：

10.1007/s10067-012-2142-x

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Autoantibodies against melanoma differentiation-associated gene 5 (MDA5) are important serological markers in dermatomyositis (DM) with rapidly progressive interstitial lung disease (ILD). Recent studies noted that anti-MDA5 antibody (anti-MDA5ab), ferritin, and IL-18 are useful biomarkers for evaluating the responses to treatment and the status of ILD in anti-MDA5ab-positive DM. In this study, we further studied the importance of anti-MDA5ab levels and of ferritin and IL-18 concentrations in our patients. These biomarkers could be sometimes useful for evaluating ILD status and/or predicting the prognosis in patients with anti-MDA5ab-positive DM with several exceptional cases. A single-point evaluation of anti-MDA5ab levels and of ferritin and IL-18 concentrations has limitations in predicting the prognosis of ILD with DM. We consider that the timing of initial therapy and the anti-MDA5ab isotype, in addition to the patient's age, are also crucial factors for predicting the prognosis.

引用

页码：395 / 398

页数：4

共 16 条

[1]

Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646

[2]

Chen IJ, 2009, CLIN RHEUMATOL, V28, P639, DOI 10.1007/s10067-009-1110-6

[3]

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study [J].